In this Derm Discussions, experts review the state of clinical innovation driving new opportunities in chronic skin disease care.

Sharon Hrynkow, PhD, joins the Rare Disease Report to discuss the ultra rare and heterogenous lysosomal storage disorder. 

Roy Fleischmann, MD, discusses the recent Pfizer press release touching upon the safety of JAK inhibitors. He explains the recent scrutiny of JAKs, the concerns some rheumatologists have in regard to JAK inhibitors, and his personal opinions on prescribing JAK inhibiting drugs to his patients.

In this Derm Discussions, Brett King, MD, PhD, joins Brad Glick, DO, to discuss the potential of the JAK inhibitor class for dermatology. 

Rheumatology Network sat down with Andrew L Concoff MD, FACR, CAQSM, to discuss value-based care, including the benefits, collaborate approach to working with payers, the revenue and cost savings, and how value-based care can support routine and consistent health visits. 

Florian Thomas, MD, and Adrian Hepner, MD, cover the basics of the degenerative nerve disorder.

Stephen Russell, MD, talks about promising new data that has the potential to provide a breakthrough for treating the most common mutation of the rare genetic eye disease.

Dr. Childress said COVID-19 was difficult for many pediatric patients with ADHD